🌍·1d agoIndustry
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
Publisher
A
ARS Pharmaceuticals
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on rss.globenewswire.com
Leave the platform to read the original full article on the publisher site.
Source: ARS Pharmaceuticals
Scope: Industry
Related coverage
More related coverage
Tiziana Life Sciences·4h ago
Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function
Tempus·1d ago
Tempus and Predicta Biosciences Announce Collaboration to Expand Life Sciences Access to Ultrasensitive Whole-Genome Sequencing Assay for Hematologic Malignancies and MRD Monitoring
Alloy Therapeutics·1d ago
Alloy Therapeutics Announces $40M Series E to Scale Tech-Enabled Biotech Infrastructure
WuXi Biologics·1d ago